Effect of metoprolol on bone tissue in adult male Wistar ratsReview articles

I. Gradošová, K. Švejkovská, H. Živná, P. Živný, E. Čermáková, A. Tichý, V. Palička

Clin Osteol 2011; 16(1): 3-7

Diagnosis and treatment of bone disease in chronic kidney patients -osteoporosis or renal osteodystrophy?Short communications

V. Spustová

Clin Osteol 2011; 16(1): 8-10

Abnormalities of mineral and bone metabolism develop already in the early stages of chronic kidney disease (CKD) and progress with decline of kidney function. Bone disease may result in fractures, bone pain and deformities in growing children. Fractures occur in 47 % more commonly in elderly patients, in women, in diabetic patients, in those using glucocorticoids and in those with a longer ex­ posure to dialysis. In CKD patients with advanced decline of renal functions (stages 3-5D), bone disease is characterized as renal os­ teodystrophy which can only be exactly diagnosed by bone biopsy. Elderly patients with postmenopausal or age related osteoporosis...

Advanced secondary hyperparathyroidism in renal failure - surgical or pharmacological therapy? - Report of two casesShort communications

M. Kubišová, R. Šafránek M. Ságová, J. Horáček, M. Podhola, S. Dusilová Sulková

Clin Osteol 2011; 16(1): 11-15

The case report describes two different cases of chronic dialysis patients with secondary hyperparathyroidism, for each of whom a dif­ ferent type of therapy was selected. The first patient, despite a higher operative risk, underwent parathyroidectomy, selected mainly with respect to clinical problems. After the parathyroid glands were surgically removed, not only serum PTH levels returned to nor­ mal but many symptoms disappeared. In the other case, by contrast, long-term combined pharmacotherapy was sufficient to control serum calcium, phosphorus and PTH and the patient remained asymptomatic.

Sclerostin - a new regulatory marker of bone turnover and a key target in the treatment of osteoporosisNews

V. Cirmanová, L. Stárka

Clin Osteol 2011; 16(1): 16-19

Bone remodelling is a lifelong process of coordinated bone formation and resorption, which renews the skeleton while maintaining its structure. For this process, specialized cells are responsible: osteoblasts, osteoclasts and osteocytes. In recent years, considerable pro­ gress has been made in identifying molecular pathways involved in regulating bone metabolism. These discoveries facilitated the de­ velopment of new biochemical markers to monitor bone formation and resorption. Bone markers are useful for investigating the pa­ thophysiological processes of metabolic bone disorders and for developing new drugs for osteoporosis, rheumatoid arthritis...

11th European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ECCEO) organised together with International Osteoporosis Foundation (IOF) and European Society for Clinical and Economic Aspects of osteoporosis and Osteoarthritis (ESCEO); 23.-26. 3. 2011, Valencia, SpainNews

M. Bayer

Clin Osteol 2011; 16(1): 20-22

New books - doc. MUDr. Jaroslava Wendlová, PhD.: Biomechanical Variabels in Assessment of Fracture Risk (Slovak epidemiological Studies)Informations

J. Blahoš

Clin Osteol 2011; 16(1): 23

News from around the worldLiterature

Clin Osteol 2011; 16(1): 24-28